<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03303079</url>
  </required_header>
  <id_info>
    <org_study_id>406-102-00001</org_study_id>
    <secondary_id>JapicCTI-173723</secondary_id>
    <nct_id>NCT03303079</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of subcutaneous (SC) administration of TEV-48125 [monthly
      TEV-48125 225 mg (loading dose only: 675 mg) and TEV-48125 675 mg once over a period of 3
      months] compared with placebo for preventive treatment in Chronic Migraine patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2017</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in the monthly (28-day) average number of headache days of at least moderate severity during the 12-week period after the first dose of Interventional Medicinal Product(IMP)</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients reaching at least 50% reduction in the monthly average number of headache days of at least moderate severity</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in the monthly average number of days of use of any acute migraine medications</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in the number of headache days of at least moderate severity</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in the monthly average number of migraine days during the 12-week period after the 1st dose of study drug</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">540</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>TEV-48125 (675/225/225 mg) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TEV-48125 will be subcutaneously administered once monthly for 3 months (675/225/225 mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TEV-48125 (675 mg/placebo/placebo) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months (675 mg/placebo/placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be subcutaneously administered once monthly for 3 months (placebo/placebo/placebo).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TEV-48125</intervention_name>
    <description>TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months.</description>
    <arm_group_label>TEV-48125 (675/225/225 mg) group</arm_group_label>
    <arm_group_label>TEV-48125 (675 mg/placebo/placebo) group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be subcutaneously administered once monthly for 3 months.</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with migraine onset at â‰¤50 years of age

          -  Patient signs and dates the informed consent document

          -  Patient has history of migraine according to International Classification of Headache
             Disorders, or clinical judgment suggests a migraine diagnosis

          -  85% e-diary compliance

        Exclusion Criteria:

          -  Clinically significant hematological, cardiac, renal, endocrine, pulmonary,
             gastrointestinal, genitourinary, neurologic, hepatic, or ocular disease, at the
             discretion of the investigator

          -  Evidence or medical history of clinically significant psychiatric issues, including
             any suicide attempt in the past, or suicidal ideation with a specific plan in the past
             2 years

          -  History of clinically significant cardiovascular disease or vascular ischemia (such as
             myocardial, neurological [eg, cerebral ischemia], peripheral extremity ischemia, or
             other ischemic event) or thromboembolic events (arterial or venous thrombotic or
             embolic events), such as cerebrovascular accident (including transient ischemic
             attacks), deep vein thrombosis, or pulmonary embolism

          -  Known infection or history of human immunodeficiency virus, tuberculosis, or chronic
             hepatitis B or C infection

          -  Past or current history of cancer in the last 5 years, except for appropriately
             treated nonmelanoma skin carcinoma

          -  Pregnant or nursing females

          -  History of hypersensitivity reactions to injected proteins, including monoclonal
             antibodies

          -  medicine within 2 months prior to study drug administration or 5 half-lives, whichever
             is longer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroaki Ono</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Drug Information Center</last_name>
    <phone>+81-3-6361-7314</phone>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Kanto Region</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2017</study_first_submitted>
  <study_first_submitted_qc>October 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2017</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

